Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23997278 | 0.85 | SMN1; SMN2 (0.52) | ALDH1A1KDM4EHPGDL3MBTL1TDP1 | |
| SCHEMBL14197642 | 0.83 | TDP1 (0.65) | ALDH1A1L3MBTL1TDP1 | |
| SCHEMBL14197636 | 0.79 | SIGMAR1 (0.50) | — | |
| SCHEMBL4601440 | 0.78 | CA1 (0.59) | ALDH1A1KDM4EHPGDL3MBTL1CYP19A1 | |
| SCHEMBL1563414 | 0.77 | NR3C2 (0.49) | ALDH1A1KDM4EHPGD | |
| SCHEMBL4851833 | 0.76 | ALDH1A1 (0.58) | ALDH1A1KDM4EL3MBTL1CYP19A1 | |
| Bromide SCHEMBL11513156 | 0.75 | NR3C2 (0.47) | ALDH1A1KDM4EHPGD | |
| Bromide SCHEMBL10618379 | 0.75 | NR3C2 (0.47) | ALDH1A1KDM4EHPGD | |
| SCHEMBL14197639 | 0.74 | HPGD (0.59) | ALDH1A1HPGD | |
| SCHEMBL4600923 | 0.74 | LMNA (0.55) | ALDH1A1KDM4ECYP19A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | ALDH1A1 935/4885KDM4E 447/4885HPGD 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.